Literature DB >> 19224126

A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases.

Pál Soltész1, Henriett Dér, György Kerekes, Péter Szodoray, Gabriella Szücs, Katalin Dankó, Yehuda Shoenfeld, Gyula Szegedi, Zoltán Szekanecz.   

Abstract

Patients with autoimmune diseases may have increased vascular risk leading to higher mortality rates. Novel imaging techniques are necessary for the early assessment and management of these patients. In this study, we compared augmentation index (AIx) and pulse wave velocity (PWV), indicators of arterial stiffness, to brachial arterial flow-mediated vasodilation (FMD) and common carotid artery intima-media thickness (ccIMT), standard indicators of endothelial dysfunction and atherosclerosis, respectively. We wished to assess the vascular status of autoimmune patients by using a novel, cheap, and reproducible technique, the arteriograph. Altogether, 101 patients with systemic autoimmune diseases including primary antiphospholipid syndrome, systemic sclerosis, rheumatoid arthritis, and polymyositis, all having various types of vasculopathies, as well as 36 healthy individuals were investigated. Arterial stiffness was assessed by a TensioClinic arteriograph, a recently validated technique. Brachial arterial FMD and ccIMT were determined using high-resolution ultrasonography. Autoimmune patients exerted impaired FMD (3.7 +/- 3.8%), increased ccIMT (0.7 +/- 0.2 mm), AIx (1.2 +/- 32.2%), and PWV (9.7 +/- 2.4 m/s) in comparison to control subjects (FMD = 8.4 +/- 4.0%; ccIMT = 0.6 +/- 0.1 mm; Aix = -41.1 +/- 22.5%; PWV = 8.0 +/- 1.5 m/s; p < 0.05). We found a significant negative correlation of FMD with AIx (R = -0.64; p < 0.0001) and PWV (R = -0.37; p = 0.00014). There were significant positive correlations between ccIMT and AIx (R = 0.34; p = 0.0009), ccIMT and PWV (R = 0.44; p < 0.0001), as well as AIx and PWV (R = 0.47; p < 0.0001). AIx, PWV, and ccIMT positively correlated and FMD negatively correlated with the age of the autoimmune patients. Arterial stiffness indicated by increased AIx and PWV may be strongly associated with endothelial dysfunction and overt atherosclerosis in patients with autoimmune diseases. Assessment of arterial stiffness, FMD, and ccIMT are reproducible and reliable noninvasive techniques for the complex assessment of vascular abnormalities in patients at high risk.

Entities:  

Mesh:

Year:  2009        PMID: 19224126     DOI: 10.1007/s10067-009-1118-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  42 in total

1.  Atherogenesis: current understanding of the causes of atheroma.

Authors:  P L Weissberg
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

2.  [Blood pressure and arterial stiffness. A comparison of two devices for measuring augmentationindex and pulse wave velocity].

Authors:  Dieter Magometschnigg
Journal:  Wien Med Wochenschr       Date:  2005-09

3.  Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction.

Authors:  P Soltesz; H Der; K Veres; R Laczik; S Sipka; G Szegedi; P Szodoray
Journal:  Rheumatology (Oxford)       Date:  2008-09-09       Impact factor: 7.580

4.  TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines--immunological alterations in acute coronary syndrome and stable coronary artery disease.

Authors:  P Szodoray; O Timar; K Veres; H Der; E Szomjak; G Lakos; M Aleksza; B Nakken; G Szegedi; P Soltesz
Journal:  Scand J Immunol       Date:  2006-09       Impact factor: 3.487

5.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

6.  Impact of aortic stiffness on survival in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; M E Safar; G M London
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

7.  Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.

Authors:  Katalin Dankó; Andrea Ponyi; Tamás Constantin; Gábor Borgulya; Gyula Szegedi
Journal:  Medicine (Baltimore)       Date:  2004-01       Impact factor: 1.889

8.  Antiphospholipid antibodies in acute coronary syndrome.

Authors:  K Veres; G Lakos; A Kerényi; Z Szekanecz; G Szegedi; Y Shoenfeld; P Soltész
Journal:  Lupus       Date:  2004       Impact factor: 2.911

Review 9.  Atherosclerosis and the antiphospholipid syndrome: a link unravelled?

Authors:  Y Shoenfeld; D Harats; J George
Journal:  Lupus       Date:  1998       Impact factor: 2.911

10.  ECG abnormalities in polymyositis.

Authors:  R Stern; J H Godbold; Q Chess; L J Kagen
Journal:  Arch Intern Med       Date:  1984-11
View more
  26 in total

1.  Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis.

Authors:  Edit Végh; György Kerekes; Anita Pusztai; Attila Hamar; Szilvia Szamosi; Andrea Váncsa; Levente Bodoki; Lilla Pogácsás; Fruzsina Balázs; Katalin Hodosi; Andrea Domján; Sándor Szántó; Zoltán Nagy; Zoltán Szekanecz; Gabriella Szűcs
Journal:  Rheumatol Int       Date:  2019-12-17       Impact factor: 2.631

Review 2.  Validated methods for assessment of subclinical atherosclerosis in rheumatology.

Authors:  György Kerekes; Pál Soltész; Michael T Nurmohamed; Miguel A Gonzalez-Gay; Maurizio Turiel; Edit Végh; Yehuda Shoenfeld; Iain McInnes; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2012-02-21       Impact factor: 20.543

3.  Decreased flow-mediated dilatation with increased arterial stiffness and thickness as early signs of atherosclerosis in polymyositis and dermatomyositis patients.

Authors:  Melinda Vincze; H Dér; Gy Kerekes; P Szodoray; M Zeher; K Dankó; P Soltész
Journal:  Clin Rheumatol       Date:  2014-03-12       Impact factor: 2.980

Review 4.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

5.  Cyclooxygenase inhibition augments central blood pressure and aortic wave reflection in aging humans.

Authors:  Jill N Barnes; Darren P Casey; Casey N Hines; Wayne T Nicholson; Michael J Joyner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-13       Impact factor: 4.733

6.  Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  De-Guang Wang; Xiao-Wu Tang; Ye Fan; Rui-Xue Leng; Jing Ni; Sen-Miao Deng; Chao Wang; Han Cen; Hai-Feng Pan; Dong-Qing Ye
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

7.  Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy.

Authors:  Michelle J Ormseth; Annette M Oeser; Andrew Cunningham; Aihua Bian; Ayumi Shintani; Joseph Solus; S Bobo Tanner; C Michael Stein
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

8.  Stiffening of aorta is more preferentially associated with rheumatoid arthritis than peripheral arteries.

Authors:  Yong Yang; Zhen Wang; Zihao Fu; Runrun Yang; Jia Wang; Lijun Yuan; Feng Gao; Yunyou Duan
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

Review 9.  Vascular effects of biologic agents in RA and spondyloarthropathies.

Authors:  Zoltán Szekanecz; György Kerekes; Pál Soltész
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

10.  Prevalence of arterial stiffness and the risk of myocardial diastolic dysfunction in women.

Authors:  Ute Seeland; Anna Brecht; Ahmad T Nauman; Sabine Oertelt-Prigione; Mirjam Ruecke; Fabian Knebel; Verena Stangl; Vera Regitz-Zagrosek
Journal:  Biosci Rep       Date:  2016-10-27       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.